Does Rallies show Form 4 insider transactions for IMRX?

Yes. Rallies tracks IMRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IMRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IMRX. It does not provide personalized investment advice.

IMRX (Immuneering Corporation Class A Common Stock) Stock Analysis - Insider Trades

Immuneering Corporation Class A Common Stock (IMRX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMRX trades at $4.97 with a market cap of $315.08M and a P/E ratio of -3.91. IMRX moved +2.97% today. Year to date, IMRX is -24.05%; over the trailing twelve months it is +219.75%. Its 52-week range spans $1.10 to $10.08. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces IMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IMRX stock inside the company?

Recent IMRX insider activity includes Brakewood Harold Eugene bought 5.25K, Schall Thomas J. bought 21.64K, Hall Brett Matthew bought 2.30K, Neufeld Leah R bought 2.63K, and Feinberg Peter bought 20.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IMRX Key Metrics

Key financial metrics for IMRX
Metric	Value
Price	$4.97
Market Cap	$315.08M
P/E Ratio	-3.91
EPS	$-1.27
Dividend Yield	0.00%
52-Week High	$10.08
52-Week Low	$1.10
Volume	8.69K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-56.02M
Gross Margin	0.00%

Recent IMRX Insider Trades

Brakewood Harold Eugene bought 5.25K (~$24.99K) on Jan 16, 2026.
Schall Thomas J. bought 21.64K (~$101.04K) on Jan 15, 2026.
Hall Brett Matthew bought 2.30K (~$10.50K) on Jan 15, 2026.
Neufeld Leah R bought 2.63K (~$10.91K) on Jan 13, 2026.
Feinberg Peter bought 20.00K (~$86.90K) on Jan 12, 2026.

Latest IMRX News

Phase 2a Pancreatic Cancer Trial Delivers 64% 12-Month OS, Shares Plunge 26.5% — Jan 8, 2026

IMRX Analyst Consensus

5 analysts cover IMRX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.

Common questions about IMRX

Who is trading IMRX stock inside the company?: Recent IMRX insider activity includes Brakewood Harold Eugene bought 5.25K, Schall Thomas J. bought 21.64K, Hall Brett Matthew bought 2.30K, Neufeld Leah R bought 2.63K, and Feinberg Peter bought 20.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IMRX?: Yes. Rallies tracks IMRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IMRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IMRX. It does not provide personalized investment advice.